142P Phase IIIb study of durvalumab plus platinum–etoposide in first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): Treatment patterns of chemotherapy combination phase with durvalumab

Isla, Dolores; Arriola, Edurne; Campelo, M.R. García; Martí, C.; Taín, P. Diz; Vega, A.L. Moreno; Piqueras, M.L-B.; León, L.; Calderón, V. Gutiérrez; Rodriguez, J.M. Oramas; Majem, Margarita; Sánchez-Hernández, Alfredo; Rosa, C. Aguado de la; Cabellos, R. Alvarez; Martí-Ciriquián, Juan Luis; Paul, A. Moreno; Cordero, M. Gonzalez; Mellén, Anders; Baez, L.; Zugazagoitia, Jon

doi:10.1016/j.annonc.2022.02.173

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More than half of patients (56%) were ≥65 yrs old, 34% of patients had liver metastases and 11% has BMs. According to preliminary data, the median PFS was 6.1 months, consistent with the results of CASPIAN, and notable differences were found in PFS according to the number of cycles of induction chemotherapy received (≤4 cycles: 5.4 m, >4 cycles: 6.9 m, p = 0.010) [23]. Similarly, the MAURIS trial aimed to evaluate the efficacy and safety of atezolizumab + EP in a patient population closer to clinical practice (i.e., patients with a PS ECOG 2 and/or untreated asymptomatic BMs) and-according to the interim analysis-PFS and ORR seem to be aligned to those of IMpower133 [24].…”

Section: Immunotherapy For First-line Treatment Of Es-sclcsupporting

confidence: 82%

“…As a matter of fact, real-world patients have poorer prognostic characteristics, resulting in worse survival outcomes [22]. In the CANTABRICO trial, the efficacy and safety of durvalumab + EP were assessed in a real-world ES-SCLC population in Spain (101 patients from 35 sites included) [23]. More than half of patients (56%) were ≥65 yrs old, 34% of patients had liver metastases and 11% has BMs.…”

Section: Immunotherapy For First-line Treatment Of Es-sclcmentioning

confidence: 99%

See 1 more Smart Citation

The Era of Immunotherapy in Small-Cell Lung Cancer: More Shadows Than Light?

Rossi,

Pagliaro,

Michelini

et al. 2023

Cancers

View full text Add to dashboard Cite

Small-cell lung cancer is an extremely chemo-sensitive disease; the addition of immunotherapy to chemotherapy has demonstrated a slight clinical benefit in pivotal trials, even with a statistically significant difference in terms of survival outcomes when compared to chemotherapy alone. In this scenario, the role of radiotherapy as a consolidation treatment in thoracic disease or as a prophylactic therapy in the brain should be clarified. In addition, due to the frailty and the poor prognostic characteristics of these patients, the need for predictive biomarkers that could support the use of immunotherapy is crucial. PD-L1 and TMB are not actually considered definitive biomarkers due to the heterogeneity of results in the literature. A new molecular classification of small-cell lung cancer based on the expression of key transcription factors seems to clarify the disease behavior, but the knowledge of this molecular subtype is still insufficient and the application in clinical practice far from reality; this classification could lead to a better understanding of SCLC disease and could provide the right direction for more personalized treatment. The aim of this review is to investigate the current knowledge in this field, evaluating whether there are predictive biomarkers and clinical patient characteristics that could help us to identify those patients who are more likely to respond to immunotherapy.

show abstract

Section: Immunotherapy For First-line Treatment Of Es-sclcsupporting

confidence: 82%

Section: Immunotherapy For First-line Treatment Of Es-sclcmentioning

confidence: 99%